Author(s):
Archana S. Patil, Shriraj S. Kamat, Shraja U. Birkodi, Umashri Kokatanur, Rajashree S. Masareddy, Panchaxari M. Dandagi
Email(s):
archupharma@gmail.com
DOI:
10.52711/0974-360X.2023.00342 
Address:
Archana S. Patil*, Shriraj S. Kamat, Shraja U. Birkodi, Umashri Kokatanur, Rajashree S. Masareddy, Panchaxari M. Dandagi
Department of Pharmaceutics, KLES College of Pharmacy, Belagavi,
KLE Academy of Higher Education and Research, Belagavi, Karnataka - 590010, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 5,
Year - 2023
ABSTRACT:
One of the possible routes for local and systemic delivery of hypertensive drugs has been identified as transdermal administration. Monolithic drugs in adhesive patches have the advantages of being relatively simple to manufacture and having limited dimensions of both thickness and surface area. Polyisobutene is a pressure-sensitive adhesive polymer often used in transdermal patch preparation. Polyisobutenes with varying molecular weight distributions have differing viscosities, which can affect drug release. In the current study, Atenolol transdermal patches were made with different proportions of low and high molecular weight polyisobutene and ethyl cellulose as a thickening agent. Prepared patches were evaluated for their physicochemical properties like thickness, weight variation, folding endurance, tensile strength, moisture content, drug content and in- vitro permeation rate. Based on tensile strength (1.92kg/mm2), folding endurance (343) and in-vitro permeation rate (85.79%) at the end of 30th hour, F1 formulation was found to be optimum. Ex vivo permeation study was carried out using rat skin and 67.09% drug permeated at the end of 30th hour. Formulations were subjected to stability studies for 60 days and were found to be stable. Thus, an ideal combination of polyisobutenes in the ratio 3:1 (High Molecular Weight: Low Molecular Weight) and ethyl cellulose (200mg) would serve as the best choice for fabrication of Atenolol patches for its sustained effect.
Cite this article:
Archana S. Patil, Shriraj S. Kamat, Shraja U. Birkodi, Umashri Kokatanur, Rajashree S. Masareddy, Panchaxari M. Dandagi. Fabrication of Polyisobutene Based Matrix Patches for Transdermal Delivery of Atenolol. Research Journal of Pharmacy and Technology 2023; 16(5):2085-0. doi: 10.52711/0974-360X.2023.00342
Cite(Electronic):
Archana S. Patil, Shriraj S. Kamat, Shraja U. Birkodi, Umashri Kokatanur, Rajashree S. Masareddy, Panchaxari M. Dandagi. Fabrication of Polyisobutene Based Matrix Patches for Transdermal Delivery of Atenolol. Research Journal of Pharmacy and Technology 2023; 16(5):2085-0. doi: 10.52711/0974-360X.2023.00342 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-5-1
REFERENCES:
1. Saju MD, Allagh KP, Scaria L, Joseph S, Thiyagarajan JA. Prevalence, awareness, treatment, and control of hypertension and its associated risk factors: results from baseline survey of SWADES family cohort study. International Journal of Hypertension. 2020 Oct;2020.
2. Sakthikumar R, Lathaeswari R, Senthamarai R, Suriyaprakash TN, Anithaa A. Formulation and Evaluation of PropanololHCl Controlled Porosity Osmotically Controlled Tablet. Research Journal of Pharmaceutical Dosage Forms and Technology. 2010;2(6):378-80.
3. Vyas S, Khar R, Controlled Drug Delivery-Concepts and Advances, VallabhPrakashan, New Delhi (1st edition).241-248.
4. Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed A. Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharm. 2019 Jun 1;69(2):197-215. doi: 10.2478/acph-2019-0016
5. Singh JV, Singh SJ, Kumar SA, Mehra GR, Anil S, Kumar JR. Design, formulation and in vitro drug release from transdermal patches containing Nebivolol hydrochloride as model drug. Asian Journal of Pharmaceutical Research. 2012;2(4):136-41.
6. T. Venkateswara Rao, Owku Ravi Kiran. Review: Transdermal patch. Research J. Pharma. Dosage Forms and Tech. 2013; 5(1): 12-16.doi:10.31032/IJBPAS/2021/10.12.1010
7. Banu TS, Sandhya KV, Jayaveera KN. Approaches and Current Trends of Transdermal Drug Delivery System-A Review. Research Journal of Pharmaceutical Dosage Forms and Technology. 2013;5(4):177-90.
8. Bozorg BD, Banga AK. Effect of Different Pressure-Sensitive Adhesives on Performance Parameters of Matrix-Type Transdermal Delivery Systems. Pharmaceutics. 2020 Mar 1;12(3):209. doi: 10.3390/pharmaceutics12030209.
9. Hussain I, Narayanaswamy VB, Haque I, Hoque M. Design and Evaluation of Transdermal Patches Containing Risperidone. Asian Journal of Research in Pharmaceutical Science. 2016 Dec 1;6(4). doi:10.5958/2231-5659.2016.00030.8
10. Bhakti R. Chorghe, Swapnil T. Deshpande, Rohit D. Shah, Swati S. Korabu, Sagar V. Motarwar. Transdermal Drug Delivery System: A Review. Research J. Pharma. Dosage Forms and Tech. 2013; 5(2): 65-69.
11. Schulz M, Fussnegger B, Bodmeier R. Drug release and adhesive properties of crospovidone-containing matrix patches based on polyisobutene and acrylic adhesives. Eur J Pharm Sci. 2010 Dec 23;41(5):675-84. doi: 10.1016/j.ejps.2010.09.011.
12. Guyot M, Fawaz F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. Int J Pharm. 2000 Aug 25;204(1-2):171-82. doi: 10.1016/s0378-5173(00)00494-4.
13. Ahad A, Al-Jenoobi FI, Al-Mohizea AM, Akhtar N, Raish M, Aqil M. Systemic delivery of β-blockers via transdermal route for hypertension. Saudi Pharm J. 2015 Nov;23(6):587-602. doi: 10.1016/j.jsps.2013.12.019.
14. G.V. Wadageri, S.A. Raju, S.B. Shirsand, P. Vijay Prakash Reddy. Buccal Drug Delivery System of Atenolol. Research J. Pharm. and Tech. 5(7): July 2012: 894-900.
15. Ganti SS, Bhattaccharjee SA, Murnane KS, Blough BE, Banga AK. Formulation and evaluation of 4-benzylpiperidine drug-in-adhesive matrix type transdermal patch. Int J Pharm. 2018 Oct 25;550(1-2):71-78. doi: 10.1016/j.ijpharm.2018.08.033
16. Rangu N, Kumari BC, Akula G, Jaswanth A. Formulation and evaluation of oro dispersible tablets of atenolol by Sublimation method. Asian Journal of Pharmacy and Technology. 2018 Mar 22;8(1):01-7. doi:10.5958/2231-5713.2018.00001.6
17. Sharma P, Mittal H, Jindal R, Jindal D, Alhassan SM. Sustained delivery of atenolol drug using gum dammar crosslinked polyacrylamide and zirconium based biodegradable hydrogel composites. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2019 Feb 5;562:136-45.doi:10.1016/j.colsurfa.2018.11.039
18. Ramkanth S, Chetty CM, Sudhakar Y, Thiruvengadarajan VS, Anitha P, Gopinath C. Development, characterization &invivo evaluation of proniosomal based transdermal delivery system of Atenolol. Future Journal of Pharmaceutical Sciences. 2018 Jun 1;4(1):80-7.doi:10.1016/j.fjps.2017.10.003
19. Kusumdevi V, Asha AN, Agadi SS, Mathew D. Optimization of transdermal delivery of selected antihyperlipidaemic agents statin. J Drug Delivery Res. 2013;2:1-23.
20. Mahajan NM, Zode GH, Mahapatra DK, Thakre S, Dumore N, Gangane PS. Formulation development and evaluation of transdermal patch of piroxicam for treating dysmenorrhoea. Journal of Applied Pharmaceutical Science. 2018 Nov 30;8(11):035-41.DOI:10.7324/JAPS.2018.81105
21. Budhathoki U, Gartoulla K, Shakya S. Formulation and evaluation of transdermal patches of atenolol. Indonesian Journal of Pharmacy.2016;27. doi:10.14499/indonesianjpharm27iss4pp196.
22. Allena R., Yadav K., Sandina S. Preparation and evaluation of transdermal patches of Metformin using natural polymers. Int J Pharm Pharm Sci.2012;4(3):298-302.
23. Divya N, Hemalatha R., Nirosh M. Fabrication and evaluation of transdermal patches of Metoprolol. Int J of Res Sci.2012;2(4):138-42. doi:10.22159/ijap.2019v11i5.32759
24. Ritu G., Biswajit M. “ Development and in vitro evaluation of Diltiazem transdermal patches based on povidone- Ethyl cellulose matrices.”Drug Dev Ind Pharm. 2003; 29(1): 1-7. doi:10.1081/DDC-120016678
25. G. Vasavi, P. Naga Haritha, B. Chandrashekar. Formulation Development and In vitro Evaluation of Transdermal Patches of Tramadol HCl. Asian J. Res. Pharm. Sci. 2018; 8(3):123-129. doi:10.5958/2231-5659.2018.00021.8
26. Borges AF, Silva C, Coelho JF, Simões S. Oral films: Current status and future perspectives: I - Galenical development and quality attributes. J Control Release. 2015 May 28;206:1-19. doi:10.1016/j.jconrel.2015.03.006.
27. Shailesh T., Charmi P., Chhagan N. Formulation and Evaluation of Transdermal Patch of Repaglinide. ISRN Pharm.2011;6(5):9-19. doi: 10.5402/2011/651909
28. Anitha P, Ramkanth S, Saleem MT, Umasankari K, Reddy BP, Chetty M. Preparation, in-vitro and in-vivo characterization of transdermal patch containing glibenclamide and atenolol: a combinational approach. Pak J Pharm Sci. 2011 Apr;24(2):155-63. PMID: 21454164.
29. Latha AV, Ravikiran TN, Kumar JN. Formulation, Optimization and Evaluation of Glibenclamide Transdermal Patches by using chitosan Polymer. Asian Journal of Pharmacy and Technology. 2019;9(1):1-7. doi:10.5958/2231-5713.2019.00001.1
30. Sheth S., Mistry B. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of Eugenol. J Applied Pharm Sci.2011;1(3):96-101.
31. Harsoliya M., Patel V., Modasiya M. Development and evaluation of transdermal drug delivery system of naproxen with Chitosan for the treatment of arthritis. Int J Pharm Biol Archives. 2012; 3(2): 363-73.